Epigenetic modifications and modulators in prostate cancer

Alessia Cimadamore, Silvia Gasparrini, Marina Scarpelli, Andrea Doria, Roberta Mazzucchelli, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer (PCa) is one of the most common malignancies in men. Its clinical behavior ranges from indolent to aggressive. The clinical and morphological methods and features currently adopted show a low predictive value concerning the definition of its level of aggressiveness. Investigations have been led to understand its complex genomic landscape to improve diagnosis and prognosis as well as to define the potential role of new therapeutic targets. Epigenetic changes, including modifications in DNA methylation and histone acetylation, can contribute to the clinical behavior of PCa. MicroRNAs (miRNAs) can be used as potential biomarkers in the definition of PCa. The reversibility of epigenetic modifications opens the door to a potential perspective in the development of epigenetics modulators. The scope of this contribution is to review the main epigenetic modifications identified in PCa, including research on epigenetic modifiers and modulators.

Original languageEnglish (US)
Pages (from-to)439-450
Number of pages12
JournalCritical Reviews in Oncogenesis
Volume22
Issue number5-6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Epigenomics
Prostatic Neoplasms
DNA Methylation
Acetylation
MicroRNAs
Histones
Biomarkers
Research
Neoplasms
Therapeutics

Keywords

  • DNA methylation
  • Epigenetic modifications
  • Histone methylation
  • microRNA
  • Prostate cancer
  • Target therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cimadamore, A., Gasparrini, S., Scarpelli, M., Doria, A., Mazzucchelli, R., Massari, F., ... Montironi, R. (2017). Epigenetic modifications and modulators in prostate cancer. Critical Reviews in Oncogenesis, 22(5-6), 439-450. https://doi.org/10.1615/CRITREVONCOG.2017020964

Epigenetic modifications and modulators in prostate cancer. / Cimadamore, Alessia; Gasparrini, Silvia; Scarpelli, Marina; Doria, Andrea; Mazzucchelli, Roberta; Massari, Francesco; Cheng, Liang; Lopez-Beltran, Antonio; Montironi, Rodolfo.

In: Critical Reviews in Oncogenesis, Vol. 22, No. 5-6, 01.01.2017, p. 439-450.

Research output: Contribution to journalArticle

Cimadamore, A, Gasparrini, S, Scarpelli, M, Doria, A, Mazzucchelli, R, Massari, F, Cheng, L, Lopez-Beltran, A & Montironi, R 2017, 'Epigenetic modifications and modulators in prostate cancer', Critical Reviews in Oncogenesis, vol. 22, no. 5-6, pp. 439-450. https://doi.org/10.1615/CRITREVONCOG.2017020964
Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F et al. Epigenetic modifications and modulators in prostate cancer. Critical Reviews in Oncogenesis. 2017 Jan 1;22(5-6):439-450. https://doi.org/10.1615/CRITREVONCOG.2017020964
Cimadamore, Alessia ; Gasparrini, Silvia ; Scarpelli, Marina ; Doria, Andrea ; Mazzucchelli, Roberta ; Massari, Francesco ; Cheng, Liang ; Lopez-Beltran, Antonio ; Montironi, Rodolfo. / Epigenetic modifications and modulators in prostate cancer. In: Critical Reviews in Oncogenesis. 2017 ; Vol. 22, No. 5-6. pp. 439-450.
@article{80dd4d17ffbf4055bbd0b69a8baa720c,
title = "Epigenetic modifications and modulators in prostate cancer",
abstract = "Prostate cancer (PCa) is one of the most common malignancies in men. Its clinical behavior ranges from indolent to aggressive. The clinical and morphological methods and features currently adopted show a low predictive value concerning the definition of its level of aggressiveness. Investigations have been led to understand its complex genomic landscape to improve diagnosis and prognosis as well as to define the potential role of new therapeutic targets. Epigenetic changes, including modifications in DNA methylation and histone acetylation, can contribute to the clinical behavior of PCa. MicroRNAs (miRNAs) can be used as potential biomarkers in the definition of PCa. The reversibility of epigenetic modifications opens the door to a potential perspective in the development of epigenetics modulators. The scope of this contribution is to review the main epigenetic modifications identified in PCa, including research on epigenetic modifiers and modulators.",
keywords = "DNA methylation, Epigenetic modifications, Histone methylation, microRNA, Prostate cancer, Target therapy",
author = "Alessia Cimadamore and Silvia Gasparrini and Marina Scarpelli and Andrea Doria and Roberta Mazzucchelli and Francesco Massari and Liang Cheng and Antonio Lopez-Beltran and Rodolfo Montironi",
year = "2017",
month = "1",
day = "1",
doi = "10.1615/CRITREVONCOG.2017020964",
language = "English (US)",
volume = "22",
pages = "439--450",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "5-6",

}

TY - JOUR

T1 - Epigenetic modifications and modulators in prostate cancer

AU - Cimadamore, Alessia

AU - Gasparrini, Silvia

AU - Scarpelli, Marina

AU - Doria, Andrea

AU - Mazzucchelli, Roberta

AU - Massari, Francesco

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Prostate cancer (PCa) is one of the most common malignancies in men. Its clinical behavior ranges from indolent to aggressive. The clinical and morphological methods and features currently adopted show a low predictive value concerning the definition of its level of aggressiveness. Investigations have been led to understand its complex genomic landscape to improve diagnosis and prognosis as well as to define the potential role of new therapeutic targets. Epigenetic changes, including modifications in DNA methylation and histone acetylation, can contribute to the clinical behavior of PCa. MicroRNAs (miRNAs) can be used as potential biomarkers in the definition of PCa. The reversibility of epigenetic modifications opens the door to a potential perspective in the development of epigenetics modulators. The scope of this contribution is to review the main epigenetic modifications identified in PCa, including research on epigenetic modifiers and modulators.

AB - Prostate cancer (PCa) is one of the most common malignancies in men. Its clinical behavior ranges from indolent to aggressive. The clinical and morphological methods and features currently adopted show a low predictive value concerning the definition of its level of aggressiveness. Investigations have been led to understand its complex genomic landscape to improve diagnosis and prognosis as well as to define the potential role of new therapeutic targets. Epigenetic changes, including modifications in DNA methylation and histone acetylation, can contribute to the clinical behavior of PCa. MicroRNAs (miRNAs) can be used as potential biomarkers in the definition of PCa. The reversibility of epigenetic modifications opens the door to a potential perspective in the development of epigenetics modulators. The scope of this contribution is to review the main epigenetic modifications identified in PCa, including research on epigenetic modifiers and modulators.

KW - DNA methylation

KW - Epigenetic modifications

KW - Histone methylation

KW - microRNA

KW - Prostate cancer

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85057182480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057182480&partnerID=8YFLogxK

U2 - 10.1615/CRITREVONCOG.2017020964

DO - 10.1615/CRITREVONCOG.2017020964

M3 - Article

VL - 22

SP - 439

EP - 450

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 5-6

ER -